FDA Inspection 1035039 — Rachel M. Presti
The FDA completed an inspection of Rachel M. Presti on Nov 9, 2017 in Saint Louis, MO. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Nov 9, 2017
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Saint Louis, MO (United States)
Additional Details
Clinical Investigator (CI)